Intellipharmaceutics International Inc.
IPCI.TO
Toronto Stock Exchange0.08
CAD
-0.01
- -
Intellipharmaceutics International Inc.
IPCI.TO
(Toronto Stock Exchange)
Recent
price
0.08
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Intellipharmaceutics International Inc. (TSX:IPCI) is a pharmaceutical company specializing in the research, development, manufacture, and commercialization of novel and generic controlled-release and targeted-release oral solid dosage drugs, leveraging its proprietary Hypermatrix technology platform. The company's core products and pipeline include authorized generics such as Glucophage XR (metformin hydrochloride extended-release tablets for type 2 diabetes), Seroquel XR (quetiapine fumarate extended-release tablets for schizophrenia, bipolar disorder, and major depressive disorder), Lamictal XR (lamotrigine extended-release tablets for epilepsy), Pristiq (desvenlafaxine extended-release tablets for depression), Coreg CR (carvedilol phosphate extended-release capsules for heart failure and hypertension), and Ranexa (ranolazine extended-release tablets for chronic angina); it is also developing abuse-deterrent candidates like oxycodone hydrochloride ER (nPODDDS-based controlled-release capsules for pain), Regabatin XR (pregabalin extended-release capsules for neuropathic pain), and others targeting neurology, cardiovascular, gastrointestinal, diabetes, and pain therapeutic areas. Operations focus on the U.S. market with ANDA and NDA 505(b)(2) filings to the FDA, complemented by contract analytical services and manufacturing capabilities. Founded in 1998 by Drs. Isa and Amina Odidi and headquartered at 30 Worcester Road, Toronto, Ontario, Canada, the company previously maintained a license and commercialization agreement with Par Pharmaceutical Inc. for certain products. In recent developments, Intellipharmaceutics voluntarily delisted from the TSX at the close of March 25, 2024, transitioning to the NEX board of the TSX Venture Exchange effective March 26, 2024, amid ongoing pipeline advancement including an NDA filing for its novel Point of Divergence Drug Delivery System. Further, in June 2024, the company received a cease-trade order from the Ontario Securities Commission due to failure to file required financial statements, reflecting significant operational challenges; its shares now trade on OTC markets under IPCIQ and IPCI-H.V. These changes coincide with a strategic emphasis on abuse-deterrent opioids and complex generics in a competitive specialty pharmaceutical segment.